Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.
Vaccine protection of rhesus macaques against simian immunodeficiency virus infection.
复制标题
恒河猴免受猿猴免疫缺陷病毒感染的疫苗保护。
DOI：
10.1089/aid.1990.6.1239
复制
发表时间：
1990
影响因子：
1.5
通讯作者：
Jennings,MB
中科院分区：
文献类型：
--
作者：
Carlson,JR;McGraw,TP;Keddie,E;Yee,JL;Rosenthal,A;Langlois,AJ;Dickover,R;Donovan,R;Luciw,PA;Jennings,MB
用灭活SIVmac全苗和muramyl二肽（MDP）、不完全弗氏佐剂（IFA）或水悬液免疫的恒河猴（Macaca mulatta），静脉注射0.1 tcid50的无细胞SIVmac。在这一攻击剂量后，10只未接种疫苗的对照组中有10只的外周血淋巴细胞很容易恢复病毒，而3只接种MDP疫苗的动物、2只接种IFA疫苗的动物中的1只和3只接受水性疫苗的动物中的1只都没有恢复病毒。被保护免受攻击的动物是那些对包膜有可检测到的SIV抗体反应的动物，包括外糖蛋白（gp120）和截断的跨膜糖蛋白（gp31）。受保护的猴子在攻击前往往有较高的合胞抑制抗体滴度。攻击后的失忆反应仅在接种疫苗后感染的猴子中观察到。接种疫苗后感染病毒的动物往往比受感染的对照组活得更长。这些结果证实了另外两个灵长类动物中心的研究结果，并表明灭活的全SIV疫苗可以预防低剂量的SIV攻击，并防止那些被感染的猴子过早死亡。这种保护的机制仍未确定。这一发现使人们对最终研制出艾滋病疫苗的可能性感到乐观。
Rhesus macaques (Macaca mulatta) immunized with an inactivated whole SIVmacvaccine and muramyl dipeptide (MDP), incomplete Freund's adjuvant (IFA), or aqueous suspension were challenged intravenously with 0.1 TCID50of cell-free SIVmac. Whereas virus was readily recovered from the peripheral blood lymphocytes of 10 of 10 nonvaccinated controls following this challenge dose, virus was not recovered from the three animals that received the vaccine with MDP nor from one of two animals that received the vaccine with IFA and one of three animals that received the aqueous vaccine. The animals that were protected against challenge were those that had detectable SIV antibody response to the envelop, both the outer glycoprotein (gp120) and the truncated transmembrane glycoprotein (gp31). Protected monkeys tended to have higher titers of syncytial inhibition antibody prior to challenge. An anamnestic response after challenge was observed only in the vaccinated monkeys that became infected. Vaccinated animals that became challenge-infected tended to live longer than infected controls. These results confirm those at two other primate centers and indicate that killed whole SIV vaccines can protect against low challenge doses of SIV and prevent early death in those monkeys that do become infected. The mechanism of this protection remains undetermined. This finding adds optimism to the possibility of an eventual AIDS vaccine.